CVS Continues Preferred Status For Harvoni Over Viekira Pak
This article was originally published in The Pink Sheet Daily
Executive Summary
With the release of its formulary exclusions for 2016, CVS Health continues to prefer Gilead's HCV treatment over AbbVie's; just last week, Express Scripts continued with the opposite.
You may also be interested in...
Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs
Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.
Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs
Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.